Advertisement

Topics

Eisai Europe Ltd Company Profile

00:06 EDT 18th June 2018 | BioPortfolio

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic area for Eisai in the European market.


News Articles [240 Associated News Articles listed on BioPortfolio]

BRIEF—Eisai completes oral solid dose production facility in China

Japanese pharma major Eisai says its Chinese subsidiary, Eisai China Inc (ECI) has completed construction…

UPDATE 1-Merck, Eisai sign deal to further develop, sell Eisai cancer drug

Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in d...

Merck, Eisai in deal to further develop, sell Eisai cancer drug

NEW YORK (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already appr...

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

(Reuters) - Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many ...

Eisai Plans Invests $100M in Genetics Guided Dementia Discovery Facility in Cambridge, Mass.

Eisai Inc. is adding to its arsenal aimed at combating dementia. The company will launch the Eisai Center for Genetics Guided Dementia Discovery.

Merck and Eisai co-develop Lenvima; expand combination trials

Merck & Co. Inc. and Eisai Co. Ltd. will co-develop and co-commercialize Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) both as a monotherapy and in combination with Merck’s Keytruda (pemb...

Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan

Jointly Developed by Eisai and Saint-PlusTOKYO, Feb 27, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., L...

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

NEW YORK/TOKYO (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved ...

Drugs and Medications [15 Associated Drugs and Medications listed on BioPortfolio]

Halaven [Eisai Inc.]

These highlights do not include all the information needed to use HALAVEN™ safely and effectively. See full prescribing information for HALAVEN. HALAVEN™ (eribulin mesylate) Injection For intraven...

Lusedra [Eisai, Inc]

These highlights do not include all the information needed to use LUSEDRA safely and effectively. See full prescribing information for LUSEDRA. LUSEDRA (fospropofol disodium) Injection, for intravenou...

Ontak [Eisai, Inc]

These highlights do not include all the information needed to use Ontak safely and effectively. See full prescribing information for Ontak. ONTAK (denileukin diftitox) Injection for intravenous infusi...

Hexalen [Eisai Inc.]

HEXALEN (ALTRETAMINE) CAPSULES 50 mg R Only

Targretin [Eisai Inc.]

Targretin® (bexarotene) capsules, 75 mg

PubMed Articles [349 Associated PubMed Articles listed on BioPortfolio]

The genomic history of southeastern Europe.

Farming was first introduced to Europe in the mid-seventh millennium bc, and was associated with migrants from Anatolia who settled in the southeast before spreading throughout Europe. Here, to unders...

Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review.

In the past decade, a large influx of migrants presented in Europe. Their country of origin was mainly either Syria or Eritrea. Public health institutions in host countries in Europe are challenged to...

Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE.

Are there any changes in the treatments involving ART and IUI initiated in Europe during 2013 compared with previous years?

Hepatitis E virus genotypes and subgenotypes causing acute hepatitis, Bulgaria, 2013-2015.

In industrialized areas of the world, including Europe, Hepatitis E Virus (HEV) is considered an emerging pathogen. In fact, autochthonous cases caused by HEV genotype 3 (HEV-3) are increasingly repor...

Drought Tolerance during Reproductive Development is Important for Increasing wheat yield Potential under Climate change in Europe.

Drought stress during reproductive development could drastically reduce grain number and wheat yield, but quantitative evaluation of such effect is unknown under climate change. The objectives of this...

Clinical Trials [573 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-month...

EUROpE-RSI (EURopean Online Evaluation RSI Study)

The investigators want to identify and show differences in standards and procedures of in-hospital rapid sequence induction by collecting data with an online survey for anaesthetist in Eur...

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe

This is a prospective, non-interventional study (NIS) measuring health-related quality of life (HRQoL), treatment satisfaction, and other patient-reported outcomes (PROs) of ADPKD patients...

Companies [849 Associated Companies listed on BioPortfolio]

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Europe Ltd" on BioPortfolio

We have published hundreds of Eisai Europe Ltd news stories on BioPortfolio along with dozens of Eisai Europe Ltd Clinical Trials and PubMed Articles about Eisai Europe Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Europe Ltd Companies in our database. You can also find out about relevant Eisai Europe Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...


Corporate Database Quicklinks



Searches Linking to this Company Record